The title compound, [Cu2(C7H5O2)4(C2H6O)2], was synthesized by the reaction of benzoic acid, copper acetate and ethanol in an aqueous solution. Trypan blue dye exclusion method was used in experiment. X-ray single-crystal analysis has revealed that compound 1 (C32H32Cu2O10) crystallizes in the monoclinic system, space group C2/c, Mr = 703.66, a = 47.340(5), b = 6.6613(4), c = 22.028(2) , β = 113.284(4)°, V = 6380.6(10) 3, Z = 8, Dc = 1.465 g/cm3, F(000) = 2896, μ = 1.388 mm-1, the final R = 0.0515 and wR = 0.1172 for 5712 observed reflections with I > 2σ(I). X-ray crystal structure analysis suggests that compound [Cu2(C7H5O2)4(C2H6O)2] has a binuclear structure with two Cu(II) atoms coordinated by four benzoate groups and two ethanol molecules. The crystal packing is stabilized by intermolecular O–H···O hydrogen bonds. The compound inhibits the proliferation of K562 cells (chronic myeloid leukemic cells) significantly and dose-dependently in 48 h, and IC50 of K562 is 17.3 μg/mL by trypan blue dye exclusion method.
